CSL is currently trading at a discount, even though it owns a leading global infrastructure for plasma-derived therapies that is difficult to replicate. The company is executing a Transformation Program aiming to reduce annual pre-tax costs by $500–$550 million by fiscal year 2028, with 60% of the savings for fiscal year 2026 already achieved. Growth in the Vifor segment is strong, balancing declines in the iron franchise, while new products like ANDEMBRY and HEMGENIX are expected to drive future growth. CSL's valuation remains attractive with a forward EV/EBITDA of 10.24x and forward P/S of 2.73x, presenting a compelling opportunity for patient investors despite some temporary operational challenges.
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
An Ethereum Foundation experiment using AI agents discovered a genuine remote crash vulnerability in Ethereum validator software's GossipSub networking component. This bug could cause validator software to crash remotely, posing a denial-of-service r...
The Direxion Daily S&P 500 Bull 3X Shares (SPXL) aims to deliver three times the S&P 500's daily returns using derivatives and daily leverage resets. While it can amplify gains in strong, steady bull markets, its daily compounding and volatility can ...
Paramount Skydance's acquisition of Warner Bros. Discovery faces regulatory hurdles across the U.S., California, Brussels, and the U.K., each with different concerns. The U.S. Justice Department approved the deal, but a California court paused it ove...
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
